Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Conditions
Interventions
ALTO-100
Placebo
Locations
34
United States
Site 174
Birmingham, Alabama, United States
Site 173
Huntsville, Alabama, United States
Site 136
Chandler, Arizona, United States
Site 139
Little Rock, Arkansas, United States
Site 141
Costa Mesa, California, United States
Site 118
Fresno, California, United States
Start Date
January 10, 2023
Primary Completion Date
September 5, 2024
Completion Date
October 24, 2024
Last Updated
September 8, 2025
NCT07523048
NCT07226661
NCT07115329
NCT06793397
NCT07025720
NCT06132581
Lead Sponsor
Alto Neuroscience
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions